论文部分内容阅读
目的:探讨二甲双胍联合复方罗布麻片对2型糖尿病合并原发性高血压的降压及调脂作用。方法:140例2型糖尿病合并原发性高血压患者分为对照组和治疗组。对照组36例给予厄贝沙坦分散片150 mg/d,辛伐他汀胶囊20 mg/d,阿司匹林肠溶片100 mg/d;治疗组104例,在上述治疗的基础上给予二甲双胍缓释片500~1 000/d,复方罗布麻片2片、3次/d。对两组患者血压进行检测,记录收缩压和舒张压,2周后取空腹静脉血进行血脂化验。结果:治疗组在治疗2 w后收缩压及舒张压显著下降,6 w后血压降为正常,与治疗前相比具有极显著差异(P<0.01);治疗6~12 w后,治疗组与对照组比较差异显著(P<0.01)。治疗组治疗12周后TG、TC和LDL-C显著下降,HDL-C升高,与治疗前相比,差异显著(P<0.05)。结论:二甲双胍合并复方罗布麻片对2型糖尿病合并原发性高血压患者有在降糖的同时具有较稳定的降压和调脂效果,同时又可减少心脑血管危险因素。
Objective: To investigate the antihypertensive and lipid-lowering effects of metformin combined with compound Apocynum against type 2 diabetes mellitus patients with essential hypertension. Methods: One hundred and forty patients with type 2 diabetes mellitus complicated with essential hypertension were divided into control group and treatment group. In the control group, 36 cases were given irbesartan 150 mg / d, simvastatin 20 mg / d and aspirin 100 mg / d. The treatment group was given 104 cases of metformin sustained-release tablets 500 ~ 1 000 / d, compound Apocynum 2, 3 times / d. Two groups of patients were tested for blood pressure, systolic and diastolic blood pressure were recorded, two weeks later, fasting venous blood was taken for blood lipids test. Results: The systolic blood pressure and diastolic blood pressure of the treatment group decreased significantly after 2 weeks of treatment, and the blood pressure decreased to normal after 6 weeks, with significant difference compared with that before treatment (P <0.01). After 6 to 12 weeks of treatment, The difference between the control group was significant (P <0.01). TG, TC and LDL-C decreased significantly and HDL-C increased after treatment for 12 weeks in treatment group, which was significantly different from that before treatment (P <0.05). Conclusion: Combination of metformin and compound OBZ tablets have the effect of lowering blood sugar and stabilizing blood pressure and reducing lipid in patients with type 2 diabetes mellitus complicated with essential hypertension, meanwhile reducing cardiovascular and cardiovascular risk factors.